Mile Janevski Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Abstracts this author is presenting:

• Phase 1b/2 study to evaluate eribulin mesylate (ERI) in combination with pembrolizumab (PEM) in patients with metastatic triple-negative breast cancer (mTNBC) — Poster Session 1
• A randomized, open-label, multicenter phase 1b/2 study of eribulin mesylate in combination with PEGylated recombinant human hyaluronidase in patients (pts) with HER2–negative, high-hyaluronan metastatic breast cancer (MBC) — Poster Session 1
• Utilization and outcomes of eribulin in triple-negative metastatic breast cancer (TN MBC): real-world findings — Poster Session 1